scispace - formally typeset
Search or ask a question
Institution

University of Lausanne

EducationLausanne, Switzerland
About: University of Lausanne is a education organization based out in Lausanne, Switzerland. It is known for research contribution in the topics: Population & Medicine. The organization has 20508 authors who have published 46458 publications receiving 1996655 citations. The organization is also known as: Université de Lausanne & UNIL.


Papers
More filters
Journal ArticleDOI
TL;DR: Three subtypes have markedly better disease-free survival (DFS) after surgical resection, suggesting these patients might be spared from the adverse effects of chemotherapy when they have localized disease.
Abstract: �Colorectal cancer (CRC) is a major cause of cancer mortality. Whereas some patients respond well to therapy, others do not, and thus more precise, individualized treatment strategies are needed. To that end, we analyzed gene expression profiles from 1,290 CRC tumors using consensus-based unsupervised clustering. The resultant clusters were then associated with therapeutic response data to the epidermal growth factor receptor–targeted drug cetuximab in 80 patients. The results of these studies define six clinically relevant CRC subtypes. Each subtype shares similarities to distinct cell types within the normal colon crypt and shows differing degrees of ‘stemness’ and Wnt signaling. Subtype-specific gene signatures are proposed to identify these subtypes. Three subtypes have markedly better disease-free survival (DFS) after surgical resection, suggesting these patients might be spared from the adverse effects of chemotherapy when they have localized disease. One of these three subtypes, identified by filamin A expression, does not respond to cetuximab but may respond to cMET receptor tyrosine kinase inhibitors in the metastatic setting. Two other subtypes, with poor and intermediate DFS, associate with improved response to the chemotherapy regimen FOLFIRI 1 in adjuvant or metastatic settings. Development of clinically deployable assays for these subtypes and of subtype-specific therapies may contribute to more effective management of this challenging disease. Previous studies have identified molecular subtypes of various human cancers by gene expression profiling 2–8 , including CRC subtypes 9,10 . However, these subtypes have not been associated with outcomes in patients treated with specific therapeutic interventions. Therefore, we sought to refine the approach of molecular classification of CRC by associating gene expression profiles of CRC tumors with corresponding clinical response to cetuximab. We first used consensusbased non-negative matrix factorization (NMF) 11 to cluster two published gene expression data sets (GSE13294 (ref. 12) and GSE14333 (ref. 13)) derived from resected primary CRCs (core data sets, n = 445). These data were corrected for batch effects and merged using the distance-weighted discrimination method 5,14 before clustering. This analysis defined five distinct high-consensus molecular subtypes of CRC (Supplementary Fig. 1a–e and Supplementary Results and

847 citations

Journal ArticleDOI
Oliver A. Cornely, Ana Alastruey-Izquierdo1, Dorothee Arenz2, Sharon C.-A. Chen3, Eric Dannaoui4, Bruno Hochhegger5, Bruno Hochhegger6, Martin Hoenigl7, Martin Hoenigl8, Henrik Jeldtoft Jensen9, Katrien Lagrou10, Russell E. Lewis11, Sibylle C. Mellinghoff2, Mervyn Mer12, Zoi D. Pana13, Danila Seidel2, Donald C. Sheppard14, Roger Wahba2, Murat Akova15, Alexandre Alanio16, Abdullah M. S. Al-Hatmi17, Sevtap Arikan-Akdagli15, Hamid Badali18, Ronen Ben-Ami19, Alexandro Bonifaz20, Stéphane Bretagne16, Elio Castagnola21, Methee Chayakulkeeree22, Arnaldo Lopes Colombo23, Dora E. Corzo-Leon24, Lubos Drgona25, Andreas H. Groll26, Jesús Guinea27, Jesús Guinea28, Claus Peter Heussel29, Ashraf S. Ibrahim30, Souha S. Kanj31, Nikolay Klimko, Michaela Lackner32, Frédéric Lamoth33, Fanny Lanternier4, Cornelia Lass-Floerl32, Dong-Gun Lee34, Thomas Lehrnbecher35, Badre E. Lmimouni, Mihai Mares, Georg Maschmeyer, Jacques F. Meis, Joseph Meletiadis36, Joseph Meletiadis37, C. Orla Morrissey38, Marcio Nucci39, Rita O. Oladele, Livio Pagano40, Alessandro C. Pasqualotto41, Atul Patel, Zdenek Racil, Malcolm Richardson, Emmanuel Roilides13, Markus Ruhnke, Seyedmojtaba Seyedmousavi42, Seyedmojtaba Seyedmousavi18, Neeraj Sidharthan43, Nina Singh44, Janos Sinko, Anna Skiada37, Monica A. Slavin45, Monica A. Slavin46, Rajeev Soman47, Brad Spellberg48, William J. Steinbach49, Ban Hock Tan50, Andrew J. Ullmann, Joerg J. Vehreschild35, Maria J G T Vehreschild35, Thomas J. Walsh51, P. Lewis White52, Nathan P. Wiederhold53, Theoklis E. Zaoutis54, Arunaloke Chakrabarti55 
Carlos III Health Institute1, University of Cologne2, University of Sydney3, Paris Descartes University4, Universidade Federal de Ciências da Saúde de Porto Alegre5, Pontifícia Universidade Católica do Rio Grande do Sul6, University of California, San Diego7, Medical University of Graz8, University of Copenhagen9, Katholieke Universiteit Leuven10, University of Bologna11, University of the Witwatersrand12, RMIT University13, McGill University14, Hacettepe University15, University of Paris16, Utrecht University17, Mazandaran University of Medical Sciences18, Tel Aviv University19, Hospital General de México20, Istituto Giannina Gaslini21, Mahidol University22, Federal University of São Paulo23, King's College, Aberdeen24, Comenius University in Bratislava25, Boston Children's Hospital26, Complutense University of Madrid27, Hospital General Universitario Gregorio Marañón28, University Hospital Heidelberg29, University of California, Los Angeles30, American University of Beirut31, Innsbruck Medical University32, University of Lausanne33, Catholic University of Korea34, Goethe University Frankfurt35, Erasmus University Rotterdam36, National and Kapodistrian University of Athens37, Monash University38, Federal University of Rio de Janeiro39, Catholic University of the Sacred Heart40, University of Health Sciences Antigua41, National Institutes of Health42, Amrita Institute of Medical Sciences and Research Centre43, University of Pittsburgh44, Peter MacCallum Cancer Centre45, University of Melbourne46, P. D. Hinduja Hospital and Medical Research Centre47, University of Southern California48, Duke University49, Singapore General Hospital50, NewYork–Presbyterian Hospital51, Cardiff University52, University of Texas Health Science Center at San Antonio53, Children's Hospital of Philadelphia54, Post Graduate Institute of Medical Education and Research55
TL;DR: Management of mucormycosis depends on recognising disease patterns and on early diagnosis, and limited availability of contemporary treatments burdens patients in low and middle income settings.
Abstract: Mucormycosis is a difficult to diagnose rare disease with high morbidity and mortality. Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and medical intervention is lifesaving. Guidance on the complex multidisciplinary management has potential to improve prognosis, but approaches differ between health-care settings. From January, 2018, authors from 33 countries in all United Nations regions analysed the published evidence on mucormycosis management and provided consensus recommendations addressing differences between the regions of the world as part of the "One World One Guideline" initiative of the European Confederation of Medical Mycology (ECMM). Diagnostic management does not differ greatly between world regions. Upon suspicion of mucormycosis appropriate imaging is strongly recommended to document extent of disease and is followed by strongly recommended surgical intervention. First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenous isavuconazole and intravenous or delayed release tablet posaconazole are recommended with moderate strength. Both triazoles are strongly recommended salvage treatments. Amphotericin B deoxycholate is recommended against, because of substantial toxicity, but may be the only option in resource limited settings. Management of mucormycosis depends on recognising disease patterns and on early diagnosis. Limited availability of contemporary treatments burdens patients in low and middle income settings. Areas of uncertainty were identified and future research directions specified.

842 citations

Journal ArticleDOI
TL;DR: This review reviews data on the transcriptional regulation of the intermediary metabolism, i.e., glucose, amino acid, lipid, and cholesterol metabolism and discusses how transcription factors integrate signals from various pathways to ensure homeostasis.
Abstract: Our understanding of metabolism is undergoing a dramatic shift. Indeed, the efforts made towards elucidating the mechanisms controlling the major regulatory pathways are now being rewarded. At the ...

840 citations

Journal ArticleDOI
TL;DR: It is shown that ENaC plays a critical role in the adaptation of the newborn lung to air breathing and was abolished in airway epithelia from αENaC(−/−) mice that developed respiratory distress and died within 40 h of birth from failure to clear their lungs of liquid.
Abstract: The amiloride-sensitive epithelial sodium channel, ENaC, is a heteromultimeric protein made up of three homologous subunits (alpha, beta and gamma) (1,2). In vitro, assembly and expression of functional active sodium channels in the Xenopus oocyte is strictly dependent on alpha-ENaC--the beta and gamma subunits by themselves are unable to induce an amiloride-sensitive sodium current in this heterologous expression system (2). In vivo, ENaC constitutes the limiting step for sodium absorption in epithelial cells that line the distal renal tubule, distal colon and the duct of several exocrine glands. The adult lung expresses alpha, beta and gamma ENaC (3,4), and an amiloride-sensitive electrogenic sodium reabsorption has been documented in upper and lower airways (3-7), but it is not established whether this sodium transport is mediated by ENaC in vivo. We inactivated the mouse alpha-ENaC gene by gene targeting. Amiloride-sensitive electrogenic Na+ transport was abolished in airway epithelia from alpha-ENaC(-/-) mice. Alpha-ENaC(-/-) neonates developed respiratory distress and died within 40 h of birth from failure to clear their lungs of liquid. This study shows that ENaC plays a critical role in the adaptation of the newborn lung to air breathing.

840 citations

Journal ArticleDOI
TL;DR: The simple SOF index predicts risk of falls, disability, fracture, and death as well as the more complex CHS index and may provide a useful definition of frailty to identify older women at risk of adverse health outcomes in clinical practice.
Abstract: BACKGROUND: Frailty, as defined by the index derived from the Cardiovascular Health Study (CHS index), predicts risk of adverse outcomes in older adults. Use of this index, however, is impractical in clinical practice. METHODS: We conducted a prospective cohort study in 6701 women 69 years or older to compare the predictive validity of a simple frailty index with the components of weight loss, inability to rise from a chair 5 times without using arms, and reduced energy level (Study of Osteoporotic Fractures [SOF index]) with that of the CHS index with the components of unintentional weight loss, poor grip strength, reduced energy level, slow walking speed, and low level of physical activity. Women were classified as robust, of intermediate status, or frail using each index. Falls were reported every 4 months for 1 year. Disability (>/=1 new impairment in performing instrumental activities of daily living) was ascertained at 4(1/2) years, and fractures and deaths were ascertained during 9 years of follow-up. Area under the curve (AUC) statistics from receiver operating characteristic curve analysis and -2 log likelihood statistics were compared for models containing the CHS index vs the SOF index. RESULTS: Increasing evidence of frailty as defined by either the CHS index or the SOF index was similarly associated with an increased risk of adverse outcomes. Frail women had a higher age-adjusted risk of recurrent falls (odds ratio, 2.4), disability (odds ratio, 2.2-2.8), nonspine fracture (hazard ratio, 1.4-1.5), hip fracture (hazard ratio, 1.7-1.8), and death (hazard ratio, 2.4-2.7) (P < .001 for all models). The AUC comparisons revealed no differences between models with the CHS index vs the SOF index in discriminating falls (AUC = 0.61 for both models; P = .66), disability (AUC = 0.64; P = .23), nonspine fracture (AUC = 0.55; P = .80), hip fracture (AUC = 0.63; P = .64), or death (AUC = 0.72; P = .10). Results were similar when -2 log likelihood statistics were compared. CONCLUSION: The simple SOF index predicts risk of falls, disability, fracture, and death as well as the more complex CHS index and may provide a useful definition of frailty to identify older women at risk of adverse health outcomes in clinical practice. Language: en

840 citations


Authors

Showing all 20911 results

NameH-indexPapersCitations
Peer Bork206697245427
Aaron R. Folsom1811118134044
Kari Alitalo174817114231
Ralph A. DeFronzo160759132993
Johan Auwerx15865395779
Silvia Franceschi1551340112504
Matthias Egger152901184176
Bart Staels15282486638
Fernando Rivadeneira14662886582
Christopher George Tully1421843111669
Richard S. J. Frackowiak142309100726
Peter Timothy Cox140126795584
Jürg Tschopp14032886900
Stylianos E. Antonarakis13874693605
Michael Weller134110591874
Network Information
Related Institutions (5)
Utrecht University
139.3K papers, 6.2M citations

93% related

Yale University
220.6K papers, 12.8M citations

93% related

University of North Carolina at Chapel Hill
185.3K papers, 9.9M citations

92% related

University of British Columbia
209.6K papers, 9.2M citations

92% related

Boston University
119.6K papers, 6.2M citations

92% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023249
2022635
20213,970
20203,508
20193,091
20182,776